Autologous peripheral blood stem cell therapy (CellProthera)

N/A

Report date: 2026/03/20 20:03:07

Base Information

Drug NameAutologous peripheral blood stem cell therapy (CellProthera)
Drug Alias NameCellProtheraautologous peripheral blood stem cell therapy (injectable graft, myoacrdial infarction)autologous PBSC therapy (injectable graft, myoacrdial infarction)ProtheraCytes
ClassificationCell and gene therapy > Cell therapy > Source of cells > Peripheral blood-derivedCell and gene therapy > Cell therapy > Stem cell therapyCell and gene therapy > Cell therapy > Donor > Autologous
Mechanisms of ActionHematopoietic progenitor cell antigen CD34 antagonistsCell replacements
TargetsHematopoietic progenitor cell antigen CD34
Therapy Area/IndicationsMyocardial Infarction
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited KingdomFrance
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesCellprothera
China Registration ClassN/A

Develop Information

Active CompaniesBiocardia IncCellprothera
Inactive CompaniesN/A
Active IndicationsMyocardial Infarction
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A